ERBB2 and neoplasm: RC48-ADC (disitamab vedotin (DV)), a humanized HER2 targeting antibody conjugated with monomethyl auristatin E (MMAE), is a breakthrough treatment for metastatic UC that was granted approval by the Food and Drug Administration (FDA) in 2020 based on the results of RC48-C005 and RC48-C009 studies, in which RC48-ADC demonstrated a promising efficacy with a manageable safety profile in HER2-positive locally advanced or metastatic UC (mUC) patients with tumor progression after platinum-based chemotherapy (3).